Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435072 | 0.80 | TSHR (0.39) | ALDH1A1CNR2TSHR | |
| SCHEMBL10202118 | 0.80 | USP2 (0.40) | USP2CYP1A2CYP2C9MAPK1CYP2D6 | |
| SCHEMBL12193293 | 0.80 | CNR2 (0.33) | USP2CYP1A2CYP2C9CNR2TSHR | |
| SCHEMBL2683916 | 0.79 | USP2 (0.39) | USP2CYP1A2CYP2C9MAPK1CYP2D6 | |
| SCHEMBL14932818 | 0.79 | TSHR (0.34) | CYP1A2CYP2C9CYP2D6ALDH1A1CNR2 | |
| SCHEMBL15116477 | 0.79 | USP2 (0.39) | USP2CYP1A2CYP2C9MAPK1CYP2D6 | |
| SCHEMBL475482 | 0.79 | GRIN2B (0.44) | USP2JAK3HSD17B10 | |
| SCHEMBL4728514 | 0.77 | USP2 (0.38) | USP2CYP1A2CYP2C9MAPK1CYP2D6 | |
| SCHEMBL10202326 | 0.77 | USP2 (0.38) | USP2CYP1A2CYP2C9MAPK1CYP2D6 | |
| SCHEMBL4743121 | 0.77 | CYP1A2 (0.41) | USP2CYP1A2CYP2C9MAPK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013067267-A1 | ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2- [4- (BI PHENYL - 4 - YL) - 1H - IMIDAZO - 2 - YL] PYRROLIDINE - 1 - CARBONLYMETHYL} AMINE | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | USP2 3770/4885CYP1A2 275/4885CYP2C9 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.